AzTrials
AzTrials

Parkinson DiseaseNMSK-LH02NCT03727529

Immersive Virtual Reality to Improve Gait in Parkinson's Disease

A study testing Treadmill + VR and Treadmill in people with Parkinson Disease and Gait Disorders, Neurologic, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). Read more about this study

Who is it for?
Any age
Conditions the study is for
Parkinson Disease, Gait Disorders, Neurologic
What is being tested?
Treadmill + VR and Treadmill
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteBelgium
Study dates
30 Jan 2019to Jan 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Parkinson's Disease diagnosis made according to UK Brain Bank criteria
  • Hoehn and Yahr score of 1 to 3 (physically independent, able to walk unassisted)
  • Optimal drug treatment for at least 4 weeks at the time of inclusion
  • In ON phase during assessments and treatment sessions

Who cannot join

  • Other pathologies that increase risk of falling
  • Other pathologies that increase risk of nausea and vertigo
  • Contraindication to physical exercising (ACSM criteria)
  • Freezing of gait

Trial locations and contacts

1 site in 1 country.

Belgium1 site, 1 recruiting
  • Cliniques Universitaires Saint-Luc

    Brussels, 1200

    Alexis Lheureux

    Recruiting

Other trials in Belgium

About this study

Official title: Use of Immersive Virtual Reality on Treadmill to Improve Gait in Parkinson's Disease: a Single Blinded, Randomized Controlled Trial

Parkinson's Disease (PD) patients suffer from gait impairments responsible for falls and bad quality of life: reduced speed and stride length, randomness in stride duration variability (reduced Long-Range Autocorrelations (LRA)). On the other hand, treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. The purpose of this single blinded randomized controlled trial is to study the effect of a combination of immersive virtual reality and treadmill walking on LRA.

Read the detailed description

BACKGROUND

Parkinson's disease (PD) is the second most common degenerative neurological disease. PD induces gait disorders that lead to increased risk of falls. These falls seriously affect patients' quality of life and generate significant health care costs. Unfortunately, gait disorders do not respond well to drug treatments and their management is mainly based on rehabilitation treatment. The rehabilitation approach comprises two steps: a functional assessment of locomotor capacities followed by completion of a therapeutic physical exercise program.

Like heart rate, stride duration varies in the short and long term according to a complex dynamic of temporal variations. These variations present long-range autocorrelations (LRA): the stride duration does not vary randomly but in a structured way. The study of LRA is based on complex mathematical methods requiring recording of 512 consecutive gait cycles. LRA are altered in PD patients whose gait rhythm is excessively random. Alteration of LRA is correlated with neurological impairments (Hoehn \& Yahr scale and UPDRS) and patients' locomotor stability (ABC scale \& BESTest). Measurement of LRA would be the first available objective and quantitative biomarker of stability and risk of falling in patients with PD.

Guidelines concerning rehabilitation programs for PD patients are based on education (prevention of falls and inactivity,...), physical exercises, functional training (double task, complex tasks,...), learning, adaptation strategies (cueing) and action observation. The combination between immersive virtual reality (iVR) and treadmill walking will be developped.

Treadmill walking has shown long-term effectiveness on PD patients' gait and quality of life. A study carried out recently has shown that a single treadmill session reduces the stride duration variability during the intervention. There remains then to determine the long-term effect of this rehabilitation method on LRA, apart from the intervention, when walking overground. Combining iVR with treadmill walking rehabilitation offers interesting insights. Indeed, for stroke patients, this combination is more effective than classical techniques. For PD patients, non-immersive virtual reality methods (Wii, Kinect) have shown relative efficacy. Indeed, the use of non-immersive virtual reality on treadmill induces more efficient cognitive engagement and frontal lobe activation among PD patients. Non immersive VR gives longer-term effects and a greater decrease in the number of falls than without virtual reality. Furthermore, iVR makes it possible to give a functional character to reeducation and to enrich feedbacks. Indeed, iVR allows to give patients a visual flow when walking on treadmill as if they were walking overground and patients could benefit from it. But apart from a feasibility study, the therapeutic interest of iVR has not been studied yet for PD patients, especially iVR combined with treadmill walking. iVR is now easily accessible and its price is reduced, suggesting a potential for everyday clinical practice. Indeed, these new devices of good quality seem to have a good potential for neurorehabilitation. The purpose of this single blinded randomized controlled trial is then to study the effect of a comibination of immersive virtual reality and treadmill walking on LRA.

METHODS

Patients:

This study will be unicentric. 46 PD patients will be included, 23 in the intervention group and 23 in the control group. Patients will be recruited from the department of Neurology of Cliniques universitaires Saint-Luc (Brussels, Belgium). The study was approved by the local ethics committee. All patients will give informed written consent to the study. Eligibility criteria will be described in another section.

Functional assessment:

Functional assessments will cover the 3 domains of International Classification of Functioning, Disability and Health (ICF) : body functions and structures, activity and participation. Assessments will be described in another section.

LRA analysis:

At least 512 consecutive gait cycles will be recorded when walking overground at a self-selected speed on an oval track of 42 meters. The duration of each cycle will be measured using an accelerometer, placed on the head of the fibula, at an acquisition frequency of 512 Hz. LRA will be analyzed using the integrated method validated by our team for the analysis of physiological signals. This method combines calculation of the Hurst exponent (H) obtained by the Rescaled Range Analysis and the α exponent obtained by the Power Spectral Density Analysis. Consistency of the values of H and α is verified through the relation d = H-[(1 + α) / 2].

The presence of LRA can be shown with a high level of proof when these 3 conditions are met:

  • H > 0.5
  • α is significantly different from 0 and less than 1
  • d ≤ 0.10 If an inconsistency appears between H and α, the Randomly Shuffled Surrogate Data Test is applied in order to reject null hypothesis of an absence of temporal structure in studied series.

Procedure:

PD patients will follow a total of 18 treadmill exercise sessions with 3 sessions a week spread over 6 weeks. Sessions will be held at Cliniques universitaires Saint-Luc. During sessions, patients will walk 45 minutes at their comfortable speed on the treadmill with 1 pause allowed if necessary. The speed is determined according to the following technique: increase of the treadmill speed in increments of 0.10 m/s, with a starting speed of 0.15 m/s, until that the patient indicates that speed is too fast. Speed is then reduced by 0.10 m/s to have a comfortable walking speed. Every week, this walking speed will be re-evaluated. When walking on treadmill, patients will be secured with a harness (LiteGait, Mobility Research, Inc.).

Patients from the intervention group will wear a virtual reality headset while walking on the treadmill. Patients will walk in a straight line in a coherent, immersive and simple virtual environment created from a graphics software (Unity, USA). Before the first session, a 15-minute session will focus on patient familiarization with iVR.

Patients from the control group will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.

Statistical analyses:

To compare between the effect of the different treatments proposed by the two studies on LRA (primary outcome), a two-way repeated measures ANOVA (Group x Time) will be performed.

Being tested
Treadmill + VR, Treadmill
Keywords
Parkinson's Disease, Virtual reality, Long range autocorrelations
Medical subject headings
Parkinson Disease, Gait Disorders, Neurologic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treadmill + VROther

    Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR

  • TreadmillOther

    Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.

Study groups in NCT03727529
Study groupRoleWhat they receive
Intervention groupExperimentalNot described
Receives: Other: Treadmill + VR
Control groupActive comparatorNot described
Receives: Other: Treadmill

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Long-Range Autocorrelations: H exponent

    First, stride duration will be assessed using accelerometers. After this, temporal varibility of stride duration will be assessed using the Rescaled Range Analysis (H exponent) to get the Long Range Autocorrelations.

    Measured: Change from baseline in H exponent at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  2. Long-Range Autocorrelations: Alpha exponent

    First, stride duration will be assessed using accelerometers. After this, temporal varibility of stride duration will be assessed using the Power Spectral Density (Alpha exponent) to get the Long Range Autocorrelations.

    Measured: Change from baseline in Alpha exponent at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

Secondary outcomes (10)
  1. Mean gait speed

    Total walking distance (m)/ Acquisition duration (s)

    Measured: Change from baseline in mean gait speed at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  2. Step length

    Gait speed (m/s)*60/Gait cadence (steps/min)

    Measured: Change from baseline in step length at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  3. Gait cadence

    Total number of steps (#)/Acquisition duration (min)

    Measured: Change from baseline in gait cadence at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  4. Coefficient of variation of stride duration

    [SD/mean stride duration] * 100

    Measured: Change from baseline in coefficient of variation at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  5. Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS)

    A global scale about Parkinson's Disease symptoms ranging from 0-272. MDS-UPDRS part III is the motor subscale ranging from 0-132. Higher values represent a worse outcome.

    Measured: Change from baseline in MDS-UPDRS at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  6. 2 minutes walk distance

    Measured: Change from baseline in 2 minutes walk distance at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  7. Balance Evaluation Systems Test (BESTest)

    Measured: Change from baseline in BESTest at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  8. Simplified version of the Activities-specific Balance Confidence Scale (ABC-Scale)

    It is a questionnaire to assess the degree of confidence of the person in his balance associated with gestures of daily life. The score is a percentage obtained as follows: (total score obtained from the 15 items / 45) x 100. Minimum score is 0% and maximum score is 100%. Each item scores from 0 to 3. Higher values represent a better outcome.

    Measured: Change from baseline in ABC-Scale at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  9. Fall diary

    Number of falls that occur during the follow up, assessed by the patient

    Measured: Change from baseline in number of falls at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

  10. The 39-items Parkinson's Disease Questionnaire (PDQ-39)

    This is a 39 items quality of life questionnaire specific to Parkinson's disease. Each item scores from 0 to 4. The total score is from 0 to 156. Higher values represent a worse outcome.

    Measured: Change from baseline in PDQ-39 at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2018
  2. Study start30 Jan 2019
  3. Primary completionSep 2019 (estimated)
  4. Study completionJan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
46 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03727529
Sponsor's protocol ID
2018/26MAR/132
Acronym
NMSK-LH02
Status last verified
Mar 2019
First submitted
29 Oct 2018
Last updated
19 Mar 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Treadmill + VR and Treadmill in people with Parkinson Disease and Gait Disorders, Neurologic, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alexis Lheureux, MD (27645375 ext. +32, alexis.lheureux@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Long-Range Autocorrelations: H exponent (time frame: Change from baseline in H exponent at an expected average of 6 (T1), 18 (T2) and 30 (T3) weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
NMSK-LH02 Clinical Trial NCT03727529 | AzTrials